Evaluation of ABO blood group as a prognostic marker in renal cell carcinoma (RCC). (2nd December 2013)

• Record Type: Journal Article
• Authors: de Martino, Michela; Waldert, Matthias; Haitel, Andrea; Schatzl, Georg; Shariat, Shahrokh F.; Klatte, Tobias
• Is Part Of: BJU international. Volume 113:Number 5b(2014:May)
• Page Start: E62
• Page End: E66
• Publication Date: 2013-12-02
• Subjects: ABO -- blood group -- blood type -- prognosis; Genitourinary organs -- Diseases -- Periodicals; Genitourinary organs -- Surgery -- Periodicals; Urology -- Periodicals; 616.6
• DOI: 10.1111/bju.12436
• Languages: English
• ISSNs: 1464-4096

Abstract

Abstract : Objective: To evaluate ABO blood group as a prognostic marker in patients with renal cell carcinoma (RCC). Patients and Methods: This retrospective study included 556 consecutive patients who underwent surgery for RCC at a single institution. The associations of ABO blood group with clinical and pathological variables were assessed using Kruskal–Wallis and chi‐squared tests. The impact on overall survival (OS) and RCC‐specific survival (RCC‐SS) was analysed using univariable and multivariable Cox proportional hazards regression models. Results: Blood group O was associated with the absence of lymph node metastases (P = 0.034) and the presence of bilateral RCC (P = 0.017). No associations with age, gender, body mass index, Charlson comorbidity index, T stage, M stage, grade and histological subtype were observed. In univariable and multivariable survival analysis, ABO blood group was not associated with OS and RCC‐SS. Conclusions: In the present study, ABO blood group was not linked with RCC prognosis. Blood group O may be associated with the absence of lymph node metastases and the presence of bilateral RCC. External validation in larger cohorts is necessary.